TRACLEER Drug Patent Profile
✉ Email this page to a colleague
When do Tracleer patents expire, and when can generic versions of Tracleer launch?
Tracleer is a drug marketed by Actelion and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in twenty-three countries.
The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bosentan profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tracleer
A generic version of TRACLEER was approved as bosentan by SUN PHARM on April 26th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRACLEER?
- What are the global sales for TRACLEER?
- What is Average Wholesale Price for TRACLEER?
Summary for TRACLEER
| International Patents: | 28 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 111 |
| Clinical Trials: | 43 |
| Patent Applications: | 4,423 |
| Drug Prices: | Drug price information for TRACLEER |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TRACLEER |
| What excipients (inactive ingredients) are in TRACLEER? | TRACLEER excipients list |
| DailyMed Link: | TRACLEER at DailyMed |
Recent Clinical Trials for TRACLEER
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 1 |
| City of Hope Medical Center | Phase 1 |
| University of Mississippi Medical Center | Early Phase 1 |
Pharmacology for TRACLEER
| Drug Class | Endothelin Receptor Antagonist |
| Mechanism of Action | Cytochrome P450 2C9 Inducers Cytochrome P450 3A Inducers Endothelin Receptor Antagonists |
US Patents and Regulatory Information for TRACLEER
TRACLEER is protected by two US patents and two FDA Regulatory Exclusivities.
Patents protecting TRACLEER
Dispersible bosentan tablet
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dispersible bosentan tablet
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting TRACLEER
TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) IN PEDIATRIC PATIENTS AGED 3 YRS AND OLDER WITH IDIOPATHIC OR CONGENITAL PAH TO IMPROVE PULMONARY VASCULAR RESISTANCE (PVR), WHICH IS EXPECTED TO RESULT IN AN IMPROVEMENT IN EXERCISE ABILITY
Exclusivity Expiration: ⤷ Sign Up
FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actelion | TRACLEER | bosentan | TABLET, FOR SUSPENSION;ORAL | 209279-001 | Sep 5, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Actelion | TRACLEER | bosentan | TABLET;ORAL | 021290-001 | Nov 20, 2001 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Actelion | TRACLEER | bosentan | TABLET, FOR SUSPENSION;ORAL | 209279-001 | Sep 5, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Actelion | TRACLEER | bosentan | TABLET, FOR SUSPENSION;ORAL | 209279-001 | Sep 5, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Actelion | TRACLEER | bosentan | TABLET;ORAL | 021290-002 | Nov 20, 2001 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TRACLEER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Actelion | TRACLEER | bosentan | TABLET;ORAL | 021290-001 | Nov 20, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Actelion | TRACLEER | bosentan | TABLET;ORAL | 021290-002 | Nov 20, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for TRACLEER
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Janssen-Cilag International N.V. | Tracleer | bosentan | EMEA/H/C/000401 Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III.Efficacy has been shown in:, , , Primary (idiopathic and familial) PAH;, PAH secondary to scleroderma without significant interstitial pulmonary disease;, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology., , , Some improvements have also been shown in patients with PAH WHO functional class II., , Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease., |
Authorised | no | no | no | 2002-05-14 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for TRACLEER
When does loss-of-exclusivity occur for TRACLEER?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 06248593
Patent: Dispersible bosertan tablet
Estimated Expiration: ⤷ Sign Up
Austria
Patent: 51914
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0610187
Patent: tablete dispersável ou um solvato ou sal farmaceuticamente aceitável do mesmo, e excipientes farmaceuticamente aceitáveis, processo para a preparação dos mesmos, e, uso de composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 07098
Patent: COMPRIME DISPERSIBLE (DISPERSIBLE BOSERTAN TABLET)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1175484
Patent: Dispersible bosertan tablet
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 10610
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 83397
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 83397
Patent: COMPRIME DISPERSIBLE (DISPERSIBLE BOSERTAN TABLET)
Estimated Expiration: ⤷ Sign Up
Germany
Patent: 2006011150
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 20212
Patent: DISPERSIBLE BOSERTAN TABLET
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 7383
Patent: DISPERSIBLE BOSERTAN TABLET
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 19399
Estimated Expiration: ⤷ Sign Up
Patent: 08540512
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 07014454
Patent: TABLETA DE BOSENTAN DISPERSABLE. (DISPERSIBLE BOSERTAN TABLET.)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 4167
Patent: Dispersible tablet comprising 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]-benzenesulfonamide (bosutan)
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 9781
Estimated Expiration: ⤷ Sign Up
Patent: 076325
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 83397
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 83397
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 04774
Patent: ДИСПЕРГИРУЕМЫЕ ТАБЛЕТКИ БОЗЕНТАНА (DISPERSED PILLS OF BOSENTAN)
Estimated Expiration: ⤷ Sign Up
Patent: 07146395
Patent: ДИСПЕРГИРУЕМЫЕ ТАБЛЕТКИ БОЗЕНТАНА
Estimated Expiration: ⤷ Sign Up
Patent: 10129460
Patent: ДИСПЕРГИРУЕМЫЕ ТАБЛЕТКИ БОЗЕНТАНА
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 83397
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0710903
Patent: Dispersible bosertan tablet
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 080014002
Patent: DISPERSIBLE TABLET
Estimated Expiration: ⤷ Sign Up
Patent: 100093105
Patent: DISPERSIBLE TABLET
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 36943
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TRACLEER around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 2071193 | SULFONAMIDES (SULFONAMIDES) | ⤷ Sign Up |
| China | 101175484 | Dispersible bosertan tablet | ⤷ Sign Up |
| Hungary | T63152 | ⤷ Sign Up | |
| Luxembourg | 90975 | ⤷ Sign Up | |
| Czechoslovakia | 9201804 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TRACLEER
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0526708 | 02C0042 | France | ⤷ Sign Up | PRODUCT NAME: BOSENTAN MONOHYDRATE; NAT. REGISTRATION NO/DATE: EU/1/02/220/001 20020515; FIRST REGISTRATION: LI - 55841 20020228 |
| 0526708 | SPC/GB02/030 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: BOSENTAN 4-(1,1-DIMETHYLETHYL)-N-(6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2(PYRIMIDIN-2-YL)PYRIMIDIN-4-YL)BENZENESULFONAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
| 0526708 | 300097 | Netherlands | ⤷ Sign Up | |
| 0526708 | C300097 | Netherlands | ⤷ Sign Up | PRODUCT NAME: BOSENTAN, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN HYDRAAT OF IN DE VORM VAN EEN ESTER VAN DE HYDROXYLGROEP VAN DE 2-HYDROXYETHOXY REST MET EEN ZUUR MET DE FORMULE R5-OH, WAARIN R5 EEN C1-7-ALKANOYL, BENZOYL, OF HETEROCYCLYCARBONYL VOORSTELT; NATL. REGISTRATION NO/DATE: U/1/02/220/001 - 005 20020515; FIRST REGISTRATION: CH IKS 58841 01 - 02 20020228 |
| 0526708 | CA 2002 00026 | Denmark | ⤷ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
